Dacomitinib
Dacomitinib, sold under the brand name Vizimpro, is a medication for the treatment of non-small-cell lung carcinoma (NSCLC).[3] Dacomitinib has advanced to several Phase III clinical trials.In January 2014, results of the first trials were disappointing, with a failure to meet the study goals,[4][5][6] but additional Phase III trials continued.[4] In 2017, results of a trial comparing dacomitinib to gefitinib for NSCLC (driven by mutated EGFR) were announced.[7] Dacomitinib was approved for medical use in the United States in September 2018,[8] in Japan in 2019, and in the European Union in 2019;[9] for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation.